Researcher.Life Logo

American Journal of Cardiovascular Drugs : Impact Factor & More

eISSN: 1179-187XpISSN: 1175-3277

Key Metrics

CiteScore
5.9
Eigenfactor
0.001 - 0.005
H-Index
57
Impact Factor
< 5
SJR
Q2Pharmacology (medical)
SNIP
1.15
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on American Journal of Cardiovascular Drugs

American Journal of Cardiovascular Drugs Journal Specifications

Overview
Publisher ADIS INT LTD
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year2001
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in American Journal of Cardiovascular Drugs ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in American Journal of Cardiovascular Drugs

Iron Deficiency as a Modifiable Risk Factor in Heart Failure: Evidence and Recommendations.
  • 28 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Midodrine to Facilitate Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Promising Breakthrough or Just a False Hope?
  • 15 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Comment on: "A Retrospective Cohort Study on Long‑Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion".
  • 6 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with HFrEF.
  • 6 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Authors' Reply to Pang et al: "A Retrospective Cohort Study on Long-Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion".
  • 6 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Effect of Tirzepatide on Cardiovascular Outcomes.
  • 1 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Iron Deficiency as a Modifiable Risk Factor in Heart Failure: Evidence and Recommendations.
  • 28 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Midodrine to Facilitate Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Promising Breakthrough or Just a False Hope?
  • 15 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Comment on: "A Retrospective Cohort Study on Long‑Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion".
  • 6 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with HFrEF.
  • 6 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Authors' Reply to Pang et al: "A Retrospective Cohort Study on Long-Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion".
  • 6 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
Effect of Tirzepatide on Cardiovascular Outcomes.
  • 1 Oct 2025
  • American journal of cardiovascular drugs : drugs, devices, and other interventions

FAQs on American Journal of Cardiovascular Drugs